Table 2.

RRs for anal cancer, comparing females with males, SEER 18 2000–2011

FemaleMale
NIRNIRRR (95% CI)
All invasive9,73018.16,41114.11.29 (1.25–1.33)
Age, y
 <3015a380.20.41 (0.21–0.77)
 30–392283.33715.30.62 (0.52–0.73)
 40–491,43618.91,34318.11.04 (0.97–1.12)
 50–592,68342.51,67227.91.53 (1.44–1.62)
 60–692,13752.91,34637.41.42 (1.32–1.52)
 70+3,23165.91.64149.81.32 (1.25–1.41)
Race/ethnicity
 Non-Hispanic white7,79421.14,79015.21.39 (1.34–1.44)
 Black84415.284518.10.84 (0.76–0.93)
 Hispanic white73713.35189.61.38 (1.22–1.57)
 Asian/Pacific Islander2475.41674.51.19 (0.97–1.46)
 American Indian/Alaskan Native3812.7269.41.35 (0.77–2.44)
Anal site
 C21.0-Anus, NOS3,5016.52,6135.71.15 (1.09–1.21)
 C21.1-Anal canal4,0687.62,5265.51.38 (1.31–1.45)
 C21.2-Cloacogenic zone4560.81640.42.29 (1.91–2.76)
 C21.8-Overlapping lesion of rectum, anus, and anal canal1,7053.21,1082.61.23 (1.14–1.33)
Histology
 SCC8,30515.54,96910.71.45 (1.40–1.50)
 ADC9271.71,0652.50.68 (0.62–0.74)
 Melanoma1550.3990.21.24 (0.96–1.62)
 Other3430.62780.61.00 (0.85–1.17)
All in situ1,8323.54,8549.90.36 (0.34–0.38)

NOTE: IR per 1,000,000, age-adjusted to the 2000 U.S. population standard.

Statistically significant associations are presented in bold.

RRs compare female with male rates. Restricted to microscopically confirmed cases.

  • aIRs suppressed because of case counts <16.